Published in Cancer Weekly, January 3rd, 2006
"UGT1A7*3 detoxifies hydroxylated benzo-(alpha)-pyrenes and 2-hydroxyamino-1-methyl-6-phenylimidazo (4,5-beta) pyridine. The purpose of this study was to evaluate whether UGTIA7 polymorphisms are risk factors for lung cancer," investigators in Japan reported.
"A total of 113 Japanese patients with lung cancer and 178 healthy individuals were enrolled in this study. Genomic DNA was isolated from leukocytes. Exon I of UGTIA7 was sequenced. Homozygous UGTIA7*3/3 was observed in 17 (15%) of patients with lung cancer, and this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.